A preclinical study documented the antitumoral activity of ZW49 against HER-2-overexpressing and HER-2-low breast cancer cells and registered an increased binding and internalization of this ADC when compared with trastuzumab-based ADCs [105]. This evidence concerns the gene ERBB2 and breast carcinoma.